{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T09:23:20Z","timestamp":1780478600905,"version":"3.54.1"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:00:00Z","timestamp":1769731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-03024-9","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:06:32Z","timestamp":1769738792000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Comparative effects of second-line oral antidiabetic medications on atrial fibrillation risk in patients with type 2 diabetes: a nationwide retrospective cohort study"],"prefix":"10.1186","volume":"25","author":[{"given":"Ga Young","family":"Heo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seok-Jae","family":"Heo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byounghwi","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye Eun","family":"Ko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Byung","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheol Ho","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Tak","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyeok","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hyun","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shin-Wook","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkyung","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,30]]},"reference":[{"key":"3024_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1161\/CIRCRESAHA.120.316340","volume":"127","author":"J Kornej","year":"2020","unstructured":"Kornej J, B\u00f6rschel CS, Benjamin EJ, Schnabel RB. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020;127:4\u201320.","journal-title":"Circ Res"},{"key":"3024_CR2","doi-asserted-by":"publisher","first-page":"e000126","DOI":"10.1161\/JAHA.113.000126","volume":"2","author":"SA Lubitz","year":"2013","unstructured":"Lubitz SA, Moser C, Sullivan L, Rienstra M, Fontes JD, Villalon ML, et al. Atrial fibrillation patterns and risks of subsequent stroke, heart failure, or death in the community. J Am Heart Assoc. 2013;2:e000126.","journal-title":"J Am Heart Assoc"},{"key":"3024_CR3","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.amjcard.2007.10.025","volume":"101","author":"TA Aksnes","year":"2008","unstructured":"Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol. 2008;101:634\u20138.","journal-title":"Am J Cardiol"},{"key":"3024_CR4","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.1177\/2047487320908706","volume":"27","author":"Y Lee","year":"2020","unstructured":"Lee Y, Cha SJ, Park J-H, Shin J-H, Lim Y-H, Park H-C, et al. Association between insulin resistance and risk of atrial fibrillation in non-diabetics. Eur J Prev Cardiol. 2020;27:1934\u201341.","journal-title":"Eur J Prev Cardiol"},{"key":"3024_CR5","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","volume":"70","author":"CJ Lavie","year":"2017","unstructured":"Lavie CJ, Pandey A, Lau DH, Alpert MA, Sanders P. Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis: effects of weight loss and exercise. J Am Coll Cardiol. 2017;70:2022\u201335.","journal-title":"J Am Coll Cardiol"},{"key":"3024_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.yjmcc.2015.12.011","volume":"90","author":"I Russo","year":"2016","unstructured":"Russo I, Frangogiannis NG. Diabetes-associated cardiac fibrosis: cellular effectors, molecular mechanisms and therapeutic opportunities. J Mol Cell Cardiol. 2016;90:84\u201393.","journal-title":"J Mol Cell Cardiol"},{"key":"3024_CR7","first-page":"543","volume":"12","author":"C Liu","year":"2012","unstructured":"Liu C, Fu H, Li J, Yang W, Cheng L, Liu T, et al. Hyperglycemia aggravates atrial interstitial fibrosis, ionic remodeling and vulnerability to atrial fibrillation in diabetic rabbits\/Hiperglisemi diyabetik tavsanlarda atriyal interstisiyel fibrosis, iyonik remodeling ve atriyal fibrilasyon duyarliligini arttirmaktadir. Anatol J Cardiol. 2012;12:543.","journal-title":"Anatol J Cardiol"},{"issue":"7","key":"3024_CR8","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1056\/NEJMoa1611925","volume":"377","author":"B Neal","year":"2017","unstructured":"Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. New Engl J Med. 2017;377(7):644\u201357.","journal-title":"New Engl J Med"},{"key":"3024_CR9","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","volume":"373","author":"B Zinman","year":"2015","unstructured":"Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117\u201328.","journal-title":"N Engl J Med"},{"key":"3024_CR10","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMoa1812389","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357.","journal-title":"N Engl J Med"},{"key":"3024_CR11","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12872-024-04442-5","volume":"25","author":"X Liang","year":"2025","unstructured":"Liang X, Dai J, Wang F. Sodium glucose co-transporter 2 (SGLT2) inhibitors versus dipeptidyl peptidase-4 (DPP-4) inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes mellitus: a meta-analysis. BMC Cardiovasc Disord. 2025;25:59.","journal-title":"BMC Cardiovasc Disord"},{"key":"3024_CR12","doi-asserted-by":"publisher","first-page":"1379251","DOI":"10.3389\/fphar.2024.1379251","volume":"15","author":"Y Li","year":"2024","unstructured":"Li Y, Tang H, Guo Y, Shao H, Kimmel SE, Bian J, et al. Sodium-glucose cotransporter-2 inhibitors and incidence of atrial fibrillation in older adults with type 2 diabetes: a retrospective cohort analysis. Front Pharmacol. 2024;15:1379251.","journal-title":"Front Pharmacol"},{"key":"3024_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4070\/kcj.2023.0234","volume":"54","author":"M Kim","year":"2024","unstructured":"Kim M, Ha KH, Lee J, Park S, Oh KS, Bae DH, et al. Lower atrial fibrillation risk with sodium-glucose cotransporter 2 inhibitors than with dipeptidyl peptidase-4 inhibitors in individuals with type 2 diabetes: a nationwide cohort study. Korean Circ J. 2024;54:256\u201367.","journal-title":"Korean Circ J"},{"key":"3024_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-020-01105-5","volume":"19","author":"W-j Li","year":"2020","unstructured":"Li W-j, Chen X-q, Xu L-l, Li Y-q, Luo B-h. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials. Cardiovasc Diabetol. 2020;19:1\u201314.","journal-title":"Cardiovasc Diabetol"},{"key":"3024_CR15","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1016\/j.hrthm.2021.03.028","volume":"18","author":"GC Fernandes","year":"2021","unstructured":"Fernandes GC, Fernandes A, Cardoso R, Penalver J, Knijnik L, Mitrani RD, et al. Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: a meta-analysis of 34 randomized controlled trials. Heart Rhythm. 2021;18:1098\u2013105.","journal-title":"Heart Rhythm"},{"key":"3024_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12933-017-0640-5","volume":"16","author":"C-Y Chang","year":"2017","unstructured":"Chang C-Y, Yeh Y-H, Chan Y-H, Liu J-R, Chang S-H, Lee H-F, et al. Dipeptidyl peptidase-4 inhibitor decreases the risk of atrial fibrillation in patients with type 2 diabetes: a nationwide cohort study in Taiwan. Cardiovasc Diabetol. 2017;16:1\u201310.","journal-title":"Cardiovasc Diabetol"},{"key":"3024_CR17","doi-asserted-by":"publisher","first-page":"e0197245","DOI":"10.1371\/journal.pone.0197245","volume":"13","author":"Y-S Liou","year":"2018","unstructured":"Liou Y-S, Yang F-Y, Chen H-Y, Jong G-P. Antihyperglycemic drugs use and new-onset atrial fibrillation: a population-based nested case control study. PLoS ONE. 2018;13:e0197245.","journal-title":"PLoS ONE"},{"key":"3024_CR18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1001\/jama.2018.18269","volume":"321","author":"J Rosenstock","year":"2019","unstructured":"Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321:69\u201379.","journal-title":"JAMA"},{"key":"3024_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jdiacomp.2017.09.009","volume":"32","author":"S-H Ko","year":"2018","unstructured":"Ko S-H, Park Y-M, Yun J-S, Cha S-A, Choi E-K, Han K, et al. Severe hypoglycemia is a risk factor for atrial fibrillation in type 2 diabetes mellitus: nationwide population-based cohort study. J Diabetes Complications. 2018;32:157\u201363.","journal-title":"J Diabetes Complications"},{"key":"3024_CR20","doi-asserted-by":"publisher","first-page":"e009115","DOI":"10.1161\/CIRCEP.120.009115","volume":"14","author":"A Ostropolets","year":"2021","unstructured":"Ostropolets A, Elias PA, Reyes MV, Wan EY, Pajvani UB, Hripcsak G, et al. Metformin is associated with a lower risk of atrial fibrillation and ventricular arrhythmias compared with sulfonylureas: an observational study. Circ Arrhythm Electrophysiol. 2021;14:e009115.","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"3024_CR21","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1007\/s00592-021-01841-4","volume":"59","author":"J Zhou","year":"2022","unstructured":"Zhou J, Zhang G, Chang C, Chou OHI, Lee S, Leung KSK, et al. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. Acta Diabetol. 2022;59:697\u2013709.","journal-title":"Acta Diabetol"},{"key":"3024_CR22","first-page":"799","volume":"46","author":"S Cheol Seong","year":"2016","unstructured":"Cheol Seong S, Kim Y-Y, Khang Y-H, Heon Park J, Kang H-J, Lee H, et al. Data Resource Profile: The National Health Information Database of the National Health Insurance Service in South Korea. Int J Epidemiol. 2016;46:799\u2013800.","journal-title":"Int J Epidemiol"},{"key":"3024_CR23","first-page":"30","volume":"43","author":"J Kim","year":"2018","unstructured":"Kim J, Combs K, Downs J, Iii T. Medication adherence: the elephant in the room. US Pharmacist. 2018;43:30\u20134.","journal-title":"US Pharmacist"},{"issue":"Suppl 2","key":"3024_CR24","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/pds.3263","volume":"21","author":"JA Rassen","year":"2012","unstructured":"Rassen JA, Shelat AA, Myers J, Glynn RJ, Rothman KJ, Schneeweiss S. One-to-many propensity score matching in cohort studies. Pharmacoepidemiol Drug Saf. 2012;21(Suppl 2):69\u201380.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"3024_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1214\/09-STS313","volume":"25","author":"EA Stuart","year":"2010","unstructured":"Stuart EA. Matching methods for causal inference: A review and a look forward. Stat Sci. 2010;25:1\u201321.","journal-title":"Stat Sci"},{"key":"3024_CR26","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med. 2021;385:1737\u201349.","journal-title":"N Engl J Med"},{"key":"3024_CR27","doi-asserted-by":"publisher","first-page":"2599","DOI":"10.1093\/eurheartj\/ehx316","volume":"38","author":"SS Lee","year":"2017","unstructured":"Lee SS, Ae Kong K, Kim D, Lim YM, Yang PS, Yi JE, et al. Clinical implication of an impaired fasting glucose and prehypertension related to new onset atrial fibrillation in a healthy Asian population without underlying disease: a nationwide cohort study in Korea. Eur Heart J. 2017;38:2599\u2013607.","journal-title":"Eur Heart J"},{"key":"3024_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.004705","author":"YS Baek","year":"2017","unstructured":"Baek YS, Yang PS, Kim TH, Uhm JS, Park J, Pak HN, et al. Associations of abdominal obesity and new-onset atrial fibrillation in the general population. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.004705.","journal-title":"J Am Heart Assoc"},{"key":"3024_CR29","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity\u2010score matched samples. Stat Med. 2009;28:3083\u2013107.","journal-title":"Stat Med"},{"key":"3024_CR30","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1002\/sim.5984","volume":"33","author":"PC Austin","year":"2014","unstructured":"Austin PC. The use of propensity score methods with survival or time\u2010to\u2010event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33:1242\u201358.","journal-title":"Stat Med"},{"key":"3024_CR31","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496\u2013509.","journal-title":"J Am Stat Assoc"},{"key":"3024_CR32","doi-asserted-by":"publisher","first-page":"S140","DOI":"10.2337\/dc23-S009","volume":"46","author":"N ElSayed","year":"2023","unstructured":"ElSayed N, Aleppo G, Aroda V. Standards of care in diabetes\u20142023. Chapter 9. Pharmacologic approaches to glycemic treatment. Diabetes Care. 2023;46:S140\u201357.","journal-title":"Diabetes Care"},{"key":"3024_CR33","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.pharmthera.2016.11.013","volume":"172","author":"A Faria","year":"2017","unstructured":"Faria A, Persaud SJ. Cardiac oxidative stress in diabetes: mechanisms and therapeutic potential. Pharmacol Ther. 2017;172:50\u201362.","journal-title":"Pharmacol Ther"},{"key":"3024_CR34","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1007\/s11606-010-1340-y","volume":"25","author":"S Dublin","year":"2010","unstructured":"Dublin S, Glazer NL, Smith NL, Psaty BM, Lumley T, Wiggins KL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25:853\u20138.","journal-title":"J Gen Intern Med"},{"key":"3024_CR35","doi-asserted-by":"publisher","first-page":"1881","DOI":"10.1016\/j.amjcard.2019.09.009","volume":"124","author":"S Yang","year":"2019","unstructured":"Yang S, Choi E-K, Han K-D, Kwon S, Lee S-Y, Park J, et al. Risk of atrial fibrillation in relation to the time course of type 2 diabetes mellitus and fasting blood glucose. Am J Cardiol. 2019;124:1881\u20138.","journal-title":"Am J Cardiol"},{"key":"3024_CR36","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413\u201324.","journal-title":"N Engl J Med"},{"key":"3024_CR37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","volume":"383","author":"HJL Heerspink","year":"2020","unstructured":"Heerspink HJL, Stef\u00e1nsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383:1436\u201346.","journal-title":"N Engl J Med"},{"key":"3024_CR38","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","volume":"380","author":"V Perkovic","year":"2019","unstructured":"Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380:2295\u2013306.","journal-title":"N Engl J Med"},{"key":"3024_CR39","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S2213-8587(17)30258-9","volume":"5","author":"KI Birkeland","year":"2017","unstructured":"Birkeland KI, J\u00f8rgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 2017;5:709\u201317.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3024_CR40","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1161\/CIRCULATIONAHA.119.044183","volume":"141","author":"TA Zelniker","year":"2020","unstructured":"Zelniker TA, Bonaca MP, Furtado RH, Mosenzon O, Kuder JF, Murphy SA, et al. Effect of dapagliflozin on atrial fibrillation in patients with type 2 diabetes mellitus: insights from the DECLARE-TIMI 58 trial. Circulation. 2020;141:1227\u201334.","journal-title":"Circulation"},{"key":"3024_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26010209","author":"P Karakasis","year":"2024","unstructured":"Karakasis P, Theofilis P, Vlachakis PK, Korantzopoulos P, Patoulias D, Antoniadis AP, et al. Atrial fibrosis in atrial fibrillation: mechanistic insights, diagnostic challenges, and emerging therapeutic targets. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms26010209.","journal-title":"Int J Mol Sci"},{"key":"3024_CR42","doi-asserted-by":"publisher","first-page":"M146","DOI":"10.1093\/gerona\/56.3.M146","volume":"56","author":"LP Fried","year":"2001","unstructured":"Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146\u201357.","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"3024_CR43","doi-asserted-by":"publisher","first-page":"15922","DOI":"10.1038\/s41598-023-42989-z","volume":"13","author":"TA Mavrakanas","year":"2023","unstructured":"Mavrakanas TA, Tsoukas MA, Brophy JM, Sharma A, Gariani K. SGLT-2 inhibitors improve cardiovascular and renal outcomes in patients with CKD: a systematic review and meta-analysis. Sci Rep. 2023;13:15922.","journal-title":"Sci Rep"},{"key":"3024_CR44","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1016\/j.jacc.2023.04.034","volume":"81","author":"MS Usman","year":"2023","unstructured":"Usman MS, Siddiqi TJ, Anker SD, Bakris GL, Bhatt DL, Filippatos G, et al. Effect of SGLT2 inhibitors on cardiovascular outcomes across various\u00a0patient populations. J Am Coll Cardiol. 2023;81:2377\u201387.","journal-title":"J Am Coll Cardiol"},{"key":"3024_CR45","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","volume":"117","author":"WY Ding","year":"2021","unstructured":"Ding WY, Gupta D, Wong CF, Lip GY. Pathophysiology of atrial fibrillation and chronic kidney disease. Cardiovasc Res. 2021;117:1046\u201359.","journal-title":"Cardiovasc Res"},{"key":"3024_CR46","doi-asserted-by":"publisher","first-page":"912","DOI":"10.3389\/fphys.2020.00912","volume":"11","author":"X Peng","year":"2020","unstructured":"Peng X, Li L, Zhang M, Zhao Q, Wu K, Bai R, et al. Sodium-glucose cotransporter 2 inhibitors potentially prevent atrial fibrillation by ameliorating ion handling and mitochondrial dysfunction. Front Physiol. 2020;11:912.","journal-title":"Front Physiol"},{"key":"3024_CR47","doi-asserted-by":"publisher","first-page":"1011429","DOI":"10.3389\/fcvm.2022.1011429","volume":"9","author":"J Gao","year":"2022","unstructured":"Gao J, Xue G, Zhan G, Wang X, Li J, Yang X, et al. Benefits of SGLT2 inhibitors in arrhythmias. Front Cardiovasc Med. 2022;9:1011429.","journal-title":"Front Cardiovasc Med"},{"key":"3024_CR48","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1007\/s10741-022-10220-2","volume":"27","author":"S Wichaiyo","year":"2022","unstructured":"Wichaiyo S, Saengklub N. Alterations of sodium-hydrogen exchanger 1 function in response to SGLT2 inhibitors: what is the evidence? Heart Fail Rev. 2022;27:1973\u201390.","journal-title":"Heart Fail Rev"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-03024-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-03024-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T13:03:03Z","timestamp":1771851783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12933-025-03024-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,30]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3024"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-03024-9","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,30]]},"assertion":[{"value":"4 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"GYH, SJH, BK, YEK, HBK, CHP, JTP, SHH, THY, SWK, MKH, and HWK declare no competing interest relevant to this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"65"}}